The bacterium-based vaccine CRS-207, which uses a live-attenuated Listeria monocytogenes (Lm) strain ANZ-100 (Lm ΔactA/ΔinlB) engineered to express human MSLN, has been used to treat MSLN-positive cancers in clinical trials [59]. Here, MSLN is linked to cancer.